Bio-tech co. takes option for 112,000 s/f.
The expansion, on part of the fourth floor, now gives Genzyme a 112,000 s/f anchor position in the building.
Studley's David Dusek, senior managing director, Peter Capuciati, executive vice president and Alex Blue, managing director, represented Genzyme in the transaction, negotiating for the additional space to be co-terminus with the 10-year renewal Genzyme announced at the beginning of July.
"We anticipated Genzyme would act on its expansion option, but perhaps not this rapidly," said Dusek, "since growth is part of the company's long-term strategic plan."
Established in 1981, Genzyme employs more than 11,000. As of 2008, revenues were $4.6 billion.
|Printer friendly Cite/link Email Feedback|
|Comment:||Bio-tech co. takes option for 112,000 s/f.|
|Publication:||Real Estate Weekly|
|Date:||Oct 7, 2009|
|Previous Article:||Law firm expanding to 27,000 s/f on B 'way.|
|Next Article:||Winoker has three lease deals in the Handbag.|